Intermittent haloperidol treatment in mice increased 3H-spiroperidol binding to the same degree as continual haloperidol feeding. The results do not support the concept that drug holidays can reduce the incidence of tardive dyskinesia.
Increased ^3 H-spiperone binding after chronic neuroleptic treatment has been
proposed as a molecular model of tardive dyskinesia. Sulpiride has been claimed to be an
atypical neuroleptic that might not produce tardive dyskinesia. The effect of chronic sulpiride
was, therefore, compared to that of chronic haloperidol on striatal ^3 H-spiperone binding.
3 weeks of haloperidol feeding caused a 28% increase in ^3 H-spiperone binding, whereas
even very high dose sulpiride had no effect on spiperone binding. These findings support the
concept that sulpiride may be a unique neuroleptic with regard to long-term effects on dopamine
receptors.
CORRESPONDENCE essential information, to be updated at each reassess ment by the multidisciplinary team, and incorporat ing the contributions of all disciplines. New members of staff, or those dealing with emtrgencies, would need to read only a single typed sheet to acquire a grasp of the case. Forms with headings could be used for recording information, e.g.: Name, wardâ€"date of birthâ€"borough of origin dates of and reasons for admissionsâ€"treatments and special precautions, e.g. drug sensitivity general progressâ€"other medical/surgical con ditions. Present mental state (date of examination) â€"¿ nursing dependencyâ€"occupational ability links with familyâ€"-social activities-diagnostic formulation. Current treatment/rehabilitation pro gramme and aims.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.